#ChugaiPharmaceutical

In Q1 of the fiscal year ending December 2026, revenue reached JPY 321.7 billion (11.5% YoY increase), operating income was JPY 158.8 billion (16.2% YoY increase), and quarterly profit was JPY 115.4 billion (18.7% YoY increase). The number of outstanding shares was 1,679,057,667 shares.

In the first quarter of the fiscal year ending December 2026, revenue was 321.7 billion yen (YoY +11.5%), operating income was 158.8 billion yen (YoY +16.2%), and net income attributable to owners of parent was 115.4 billion yen (YoY +18.7%), achieving both higher revenue and profits.

Chugai Pharmaceutical will acquire ordinary shares totaling JPY 4,360 million from the market between May 1 and the end of May 2026, in conjunction with the introduction of a trust-type stock compensation plan.

F. Hoffman-La Roche announced its sales performance for January–March 2026. The parent company of Chugai Pharmaceutical, Roche Holding AG, holds 59.89% of the company’s shares.

The parent company, Roche Holding Limited, holds 61.12% of voting rights, maintaining management independence while continuing a strategic alliance. Roche nominates fewer than half of the directors, and a special committee is established to protect minority shareholders.

Chugai Pharmaceutical Co., Ltd. is considering reducing its investment unit to enhance stock liquidity and broaden its investor base, and has indicated a policy to carefully determine the necessity and timing of implementation.

Chugai Pharmaceutical announced that Roche will discontinue clinical development of the anti-myostatin antibody emugrobart for spinal muscular atrophy and facioscapulohumeral muscular dystrophy. Development targeting obesity will continue.

F. Hoffmann-La Roche Ltd. announced its fiscal 2025 financial results. Chugai Pharmaceutical is a consolidated subsidiary of Roche Holdings, the parent company, holding 59.89% of issued shares as of the end of December 2025.

For the fiscal year ending December 2025, revenue was JPY 1,257.9 billion (YoY +7.5%), operating income was JPY 598.8 billion (YoY +10.5%), and net income was JPY 434.0 billion (YoY +12.1%), achieving growth in both revenue and profits.

The fiscal year-end dividend for the term ending December 2025 is 147 yen per share (ordinary dividend 72 yen, 100th anniversary commemorative dividend 75 yen), raising the annual dividend to 272 yen. The total dividend amount is 241.92 billion yen, with an effective date of March 27, 2026.

Chugai Pharmaceutical will abolish the restricted stock compensation plan and introduce a trust-based stock compensation plan. Implementation is planned upon approval at the shareholders meeting on March 26, 2026.

Chugai Pharmaceutical Co., Ltd. completed the full acquisition of Renalis Pharma Co., Ltd. on November 27, 2025, and finalized the absorption-type merger with Chugai Pharmaceutical Co., Ltd. as the surviving company and Renalis Pharma Co., Ltd. as the absorbed company on December 30, 2025.